Amundi’s Denali Therapeutics DNLI Stock Holding History

Amundi’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-18,604	Closed	-$357K	–	2101
2026 Q1	$357K	Buy	+18,604	New	+$370K	﹤0.01%	1679
2025 Q2	–	Sell	-88	Closed	-$1.13K	–	1803
2025 Q1	$1.13K	Buy	88 +3	+4%	+$57	﹤0.01%	2020
2024 Q4	$1.81K	Buy	+85	New	+$2.18K	﹤0.01%	1996
2022 Q4	–	Sell	-3,017	Closed	-$96K	–	1927
2022 Q3	$96K	Hold	3,017	–	–	﹤0.01%	1561
2022 Q2	$102K	Hold	3,017	–	–	﹤0.01%	1443
2022 Q1	$97K	Hold	3,017	–	–	﹤0.01%	1477
2021 Q4	$102K	Hold	3,017	–	–	﹤0.01%	1565
2021 Q3	$152K	Hold	3,017	–	–	﹤0.01%	1472
2021 Q2	$237K	Buy	+3,017	New	+$187K	﹤0.01%	1348

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Amundi's DNLI Position: Q2 2026 in Review

Amundi sold out of Denali Therapeutics (DNLI) in Q2 2026, closing a stake of 18,604 shares — an estimated $357K sold.

Amundi first reported a position in DNLI in Q2 2021 and held it in 9 quarters. The position peaked at $357K in Q1 2026. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Amundi reported no remaining Denali Therapeutics position as of Q2 2026 after selling out during the quarter.
Amundi sold 18,604 Denali Therapeutics shares in Q2 2026, an estimated $357K.
Amundi first reported a position in Denali Therapeutics in Q2 2021 and held it in 9 quarters.
Amundi's Denali Therapeutics position peaked at $357K in Q1 2026.
292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.